“We continue to target plus 10% to plus 12% HTU adjusted IMS growth for the year.”

In context

“o be laser focused on maximizing the growth of IQOS over time, with the deployment of ZYN and VIV under its umbrella offering complementary opportunities to fully transition legal edge nicotine user from cigarette to SFPs. This context, I'm especially pleased to confirm the acceleration in IQOS HTU adjusted in market sales growth to plus 11.4% in Q2 notably driven by Europe, and including excellent progress in its largest market of Italy, We as the impact of the characterizing face of bond received our work commercial initiatives be fruit. Japan, also delivered another robust quarter of growth and other global markets accelerated nicely. While competitive activity is increasing, we see this as positive for category growth over time, and we expect continued strong high cost progress in H2. We continue to target plus 10% to plus 12% HTU adjusted IMS growth for the year. Continuous IQOS innovation on devices and consumables combined with investments in brand equity are fundamental pillars of our growth. The rollout of the Illuma Eye technology now present in over 30 markets, remains ongoing. We are expanding the portfolio of Livia tobacco free consumable, with promising initial results from recently launched new test variants and flavor capsules. We also commenced the rollout of a resin pack design on our core premium terrier HTUs as well as the expansion of our mainstream price offering, Delia, with excellent results in markets such as Germany, and Poland. In the US, we continue with small scale IQOS three pilots which are generating considerable adult consumer interest. As we progress our commercial pilot in Austin, we also launched a second pilot in Fo”